This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): darbepoetin alfa, Nespo, NESP, KRN321
Description: Aranesp is a hyperglycosylated form of erythropoetin (epo) with a longer half-life than standard epo.
Aranesp can be administered less frequently than Epogen or Procrit.
Deal Structure: Amgen has had to share rights to its first-generation recombinant epo product with Johnson & Johnson. Epogen is marketed by Amgen in the United States for chronic renal failure. Johnson & Johnson sells epo as Procrit in the U.S. for all non-renal indications and in Europe as Eprex for all indications. By contrast Amgen has retained all U.S. and European rights to Aranesp.
Amgen has an agreement with Kirin to jointly develop Aranesp through its joint venture, Kirin-Amgen. Amgen manufactures and market darbepoetin alfa in the United States, all European countries, Canada, Australia, New Zealand, Mexico, and all Central and South American countries. Kirin has similar rights for Japan, China, Taiwan, Korea, and certain other countries in Southeast Asia.
Partners: Kyowa Hakko Kirin Co., Ltd.
Additional information available to subscribers only: